Uncategorized
Phase 1b data from Kymera's KT-621 suggests 'biologic-like' efficacy in an oral pill without the ocular safety liabilities of IL-4Rα inhibitors. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice.
Metabolic
Phase 2b data confirms potent cirrhosis reversal, but safety signals may limit real-world adoption. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Analysis: Efruxifermin in F4 MASH New data from Akero Therapeutics&
Metabolic
Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * What
News
Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.
News
New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.